News

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Novo CEO’s First Test Is Winning Back the US Weight-Loss Market
Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...
Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
Danish leader will face a challenging landscape among competitors ...
Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.
Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.
Just The News10h
Trump administration considering pilot program to cover weight loss drugs under Medicare, Medicaid
The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...
Novo Nordisk A/S (NVO) Could Lose To Eli Lilly, Warns Jim Cramer
We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer ...
Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.
The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.
Why Novo Nordisk Stock Bumped Higher on Friday
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Wegovy maker Novo's profit warning triggers $70 billion share rout
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...